IL33 and Miyoshi myopathy: PDCD1 (PD‐1) and CTLA4 expression levels were remarkably higher in the low IL‐33 group, indicating that MM patients with lower IL‐33 expression levels might have a better therapeutic outcome to therapies targeting the checkpoints above (Figure 2C,D).